Article

Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN Loss

2024-08-19

Abstract excerpt

<title>Abstract</title> <p>Overcoming resistance to immune checkpoint blockade (ICB) remains a critical unmet need for most cancer patients. Loss of the PTEN tumor suppressor gene activates the PI3K-AKT pathway in multiple cancer types. In melanoma, PTEN loss reduces ICB efficacy in preclinical models and correlates with decreased response rates in patients. The PI3Kβ inhibitor GSK2636771 blocked PI3K-AKT activat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 18497e29-63b4-5013-8212-bf5c3f746b38
DOI: 10.21203/rs.3.rs-4784661/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN LossDOI 10.21203/rs.3.rs-4784661/v1Read

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.Semantic proximity Read

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in MelanomaSemantic proximity Read

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.Semantic proximity Read

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read

Idelalisib — A PI3Kδ Inhibitor for B-Cell CancersSemantic proximity Read

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatmentSemantic proximity Read

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.Semantic proximity Read

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.Semantic proximity Read

PTEN Mutations Trigger Resistance to ImmunotherapySemantic proximity Read

The phosphoinositide 3-kinase pathway and therapy resistance in cancerSemantic proximity Read

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer AgentSemantic proximity Read

Challenges in the clinical development of PI3K inhibitors.Semantic proximity Read